BenQ Medical Technology Corporation (TPEX:4116)
Taiwan · Delayed Price · Currency is TWD 39.20
-0.25 (-0.63%)
May 8, 2026, 1:30 PM CST
BenQ Medical Technology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,351 | 5,254 | 4,767 | 4,543 | 4,377 | 1,465 | |
Revenue Growth (YoY) | 8.35% | 10.21% | 4.94% | 3.80% | 198.82% | 4.55% |
Cost of Revenue | 3,630 | 3,564 | 3,319 | 3,199 | 3,129 | 952.31 |
Gross Profit | 1,720 | 1,690 | 1,448 | 1,344 | 1,247 | 512.28 |
Selling, General & Admin | 1,342 | 1,309 | 1,079 | 947.17 | 855.13 | 423.58 |
Research & Development | 35.09 | 34.69 | 36.39 | 31.96 | 39.58 | 39.65 |
Other Operating Expenses | 0.27 | - | - | -1.53 | 0.73 | 0.81 |
Operating Expenses | 1,381 | 1,347 | 1,115 | 978.46 | 896.88 | 465.82 |
Operating Income | 339.04 | 342.42 | 333.02 | 365.44 | 350.26 | 46.46 |
Interest Expense | -45.03 | -44.04 | -34.22 | -27.94 | -17.83 | -3.91 |
Interest & Investment Income | 13.32 | 12.75 | 11.23 | 10.21 | 5.24 | 0.69 |
Earnings From Equity Investments | - | - | - | -57.38 | -125.05 | 1.79 |
Currency Exchange Gain (Loss) | -22.6 | -22.6 | 8.98 | -2.5 | 3.44 | -0.53 |
Other Non Operating Income (Expenses) | 26.74 | 19.97 | 10.91 | 17.15 | 14.28 | 16.56 |
EBT Excluding Unusual Items | 311.47 | 308.5 | 329.91 | 304.98 | 230.33 | 61.06 |
Gain (Loss) on Sale of Investments | 8.8 | 8.8 | - | 5.13 | - | - |
Gain (Loss) on Sale of Assets | 17.25 | 17.25 | -0.9 | -0.03 | 3.85 | 0.06 |
Other Unusual Items | 0.03 | 0.03 | 0.37 | 0.09 | 81.57 | 0.66 |
Pretax Income | 337.54 | 334.58 | 329.38 | 310.17 | 315.74 | 61.78 |
Income Tax Expense | 119.85 | 116.96 | 92.13 | 109.91 | 79.15 | 12.75 |
Earnings From Continuing Operations | 217.69 | 217.62 | 237.25 | 200.26 | 236.6 | 49.04 |
Minority Interest in Earnings | -149.23 | -139.45 | -132.42 | -85.68 | -56.35 | -20.2 |
Net Income | 68.46 | 78.17 | 104.83 | 114.58 | 180.24 | 28.84 |
Net Income to Common | 68.46 | 78.17 | 104.83 | 114.58 | 180.24 | 28.84 |
Net Income Growth | -34.43% | -25.43% | -8.51% | -36.43% | 524.98% | -53.52% |
Shares Outstanding (Basic) | 45 | 45 | 45 | 45 | 45 | 45 |
Shares Outstanding (Diluted) | 45 | 45 | 45 | 45 | 45 | 45 |
Shares Change (YoY) | -0.58% | -0.10% | 0.02% | -0.07% | 0.42% | -0.30% |
EPS (Basic) | 1.54 | 1.75 | 2.35 | 2.57 | 4.04 | 0.65 |
EPS (Diluted) | 1.54 | 1.75 | 2.34 | 2.56 | 4.02 | 0.65 |
EPS Growth | -34.07% | -25.21% | -8.59% | -36.32% | 521.20% | -53.44% |
Free Cash Flow | 370.49 | 264.84 | 52.14 | 308.88 | 405.95 | 91.09 |
Free Cash Flow Per Share | 8.31 | 5.91 | 1.16 | 6.89 | 9.05 | 2.04 |
Dividend Per Share | 2.000 | 2.000 | 1.650 | 2.000 | 2.100 | 0.500 |
Dividend Growth | 21.21% | 21.21% | -17.50% | -4.76% | 320.00% | -50.00% |
Gross Margin | 32.16% | 32.16% | 30.38% | 29.58% | 28.50% | 34.98% |
Operating Margin | 6.34% | 6.52% | 6.98% | 8.04% | 8.00% | 3.17% |
Profit Margin | 1.28% | 1.49% | 2.20% | 2.52% | 4.12% | 1.97% |
Free Cash Flow Margin | 6.92% | 5.04% | 1.09% | 6.80% | 9.28% | 6.22% |
EBITDA | 514.52 | 519.68 | 509.07 | 532.15 | 520.51 | 107.71 |
EBITDA Margin | 9.62% | 9.89% | 10.68% | 11.71% | 11.89% | 7.36% |
D&A For EBITDA | 175.48 | 177.26 | 176.05 | 166.72 | 170.24 | 61.25 |
EBIT | 339.04 | 342.42 | 333.02 | 365.44 | 350.26 | 46.46 |
EBIT Margin | 6.34% | 6.52% | 6.98% | 8.04% | 8.00% | 3.17% |
Effective Tax Rate | 35.51% | 34.96% | 27.97% | 35.43% | 25.07% | 20.63% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.